The present disclosure relates to water dispersible or soluble diagnostic assay methods, devices, kits, and methods of manufacture.

A detection device (10), comprising a sample detection layer (1) provided thereon with a detection reagent reacted with an analyte and a result display region (18), wherein the device further comprises a symbol display layer (2) on which an indicator (21) is processed; after the indicator contacts with a gas which can change the color of the indicator, the indicator changes from a first color to a second color.

The invention encompasses a method and a device for a contactless pregnancy detection including a conical shaped main body including a first end having a first opening and a second end having a second opening, a longitudinal crease allowing the conical body to lay flat when not in use, including a pregnancy detection element mounted at an edge of the second opening, and a flap extending from the conical body to allow a user to hold the device.

The invention encompasses a method and a device for a contactless pregnancy detection including a conical shaped main body including a first end having a first opening and a second end having a second opening, a longitudinal crease allowing the conical body to lay flat when not in use, including a pregnancy detection element mounted at an edge of the second opening, and a flap extending from the conical body to allow a user to hold the device.

The present disclosure concerns luteinizing hormone receptor hormone (LHRH) compositions that can selectively bind to an LHRH receptor. Through the incorporation of radionuclides in the LHRH compositions, selective radiolabeling is made possible, allowing for identification of cells over-expressing the LHRH receptor, which is often a facet of an abnormally growing cell or a tumorigenic cell. The LHRH compositions can therefore provide for improved detection and monitoring of cancers associated with or caused by LHRH receptor over-expression.

Provided herein are devices and methods for monitoring biofluids related to ovulation. Such devices include the use of electrochemical aptamer-based (EAB) sensors.

Provided herein are devices and methods for monitoring biofluids related to ovulation. Such devices include the use of electrochemical aptamer-based (EAB) sensors.

Lateral flow methods and apparatuses for detecting one or more analytes are provided. Certain embodiments provide a lateral flow device, kit and method of using the same, comprising: a flow path defined by a permeable sub-assembly of the lateral flow device, a release zone comprising a plurality of peptide-tagged agents, and a detection zone comprising a plurality of anti-peptide agents present in the flow path at a ratio of at least 100:1, on a weight:weight basis, relative to the plurality of peptide-tagged agents.

Disclosed is a method for determining a quantitative estimate of the length of time since conception in a female mammalian subject, the method comprising: a) providing a liquid sample suspected of containing hCG; b) measuring, by means of an assay or assay device, an analyte measurement signal, whose value is dependent upon the level of hCG; c) comparing the measured signal value to an analyte threshold, wherein said analyte threshold corresponds to a time since conception; d) providing an quantitative estimate of the length of time since conception based upon the comparison in step (c).

Disclosed is a method for determining a quantitative estimate of the length of time since conception in a female mammalian subject, the method comprising: a) providing a liquid sample suspected of containing hCG; b) measuring, by means of an assay or assay device, an analyte measurement signal, whose value is dependent upon the level of hCG; c) comparing the measured signal value to an analyte threshold, wherein said analyte threshold corresponds to a time since conception; d) providing an quantitative estimate of the length of time since conception based upon the comparison in step (c).